Journal
CURRENT DRUG TARGETS
Volume 14, Issue 12, Pages 1460-1470Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450111314120011
Keywords
Barrier function; claudins; IBD; intestinal permeability; MLCK; TNF-alpha; occludin; tight junctions
Categories
Ask authors/readers for more resources
Inflammatory bowel diseases (IBD) are considered barrier diseases. After misleading initial results, the pathogenic importance of a disturbed mucosa is now widely accepted, largely because a certain percentage of first-degree relatives of patients with IBD do have permeability alterations, as assessed by oral markers. In the presence of a normal appearing gut mucosa, functional alterations of the highly dynamic inter-enterocyte tight junctions have to be considered to be responsible for the observed alterations. Indeed, various alterations of the transmembrane and intracytoplasmic proteins have been reported in IBD. An important therapeutic goal is to maintain disease remission by preservation of the correct organization of these complexes. Of the potential therapeutic approaches, the various anti-TNF agents are the best-studied agents, but other treatments may tighten the gut through as yet unknown mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available